Treatment of non-alcoholic fatty liver disease

Digestive Diseases

Volumn 32, Issue 5, 2014, Pages 597-604

  Dyson, Jessica ^a   Day, Chris ^b  

^a FREEMAN HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Management; Metabolic syndrome; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Treatment

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIRAGLUTIDE; METFORMIN; NIVOCASAN; OBETICHOLIC ACID; PENTOXIFYLLINE; PIOGLITAZONE; RESVERATROL; SULFONYLUREA DERIVATIVE; TUROFEXORATE ISOPROPYL; URSODEOXYCHOLIC ACID;

AEROBIC EXERCISE; ARTICLE; BARIATRIC SURGERY; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; DIET; DISEASE COURSE; DRUG MECHANISM; DYSLIPIDEMIA; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSTATE CANCER; RISK REDUCTION; TREATMENT INDICATION; WEIGHT REDUCTION; COMPLICATION; EXERCISE; LIFESTYLE; MOLECULARLY TARGETED THERAPY; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONFERENCE PAPER; DIET THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STAGING;

DIET; EXERCISE; HUMANS; LIFE STYLE; LIVER TRANSPLANTATION; MOLECULAR TARGETED THERAPY; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84904640647     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000360511     Document Type: Article

References (101)

1. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al: Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 2004; 40: 1387-1395.
2. Wong VW, Chu WC, Wong GL, Chan RS, Chim AM, Ong A, et al: Prevalence of nonalcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012; 61: 409-415.
3. Anstee QM, McPherson S, Day CP: How big a problem is non-alcoholic fatty liver disease? BMJ 2011; 343:d3897.
4. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of non-alcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714-1719.
5. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ: Non-alcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
6. Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sorensen TI, et al: Long-term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53: 750-755.
7. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al: Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873.
8. Wanless IR, Lentz JS: Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-1110.
9. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al: Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-131.
10. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al: Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873.
11. Anstee QM, Targher G, Day CP: Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10: 330-344.
12. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
13. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al: The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023.
14. Dyson JK, McPherson S, Anstee QM: Nonalcoholic fatty liver disease: non-invasive investigation and risk stratification. J Clin Pathol 2013; 66: 1033-1045.
15. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP: Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 1265-1269.
16. Angulo P, Hui J, Marchesini G, Bugianesi E, George J, Farrell GC, et al: The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 847-854.
17. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al: Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-1713.
18. Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, et al: Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454-462.
19. Castera L, Foucher J, Bernard PH, Carvalho F, Allaix D, Merrouche W, et al: Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010; 51: 828-835.
20. Myers RP, Pomier-Layrargues G, Kirsch R, Pollett A, Beaton M, Levstik M, et al: Discordance in fibrosis staging between liver biopsy and transient elastography using the Fibro- Scan XL probe. J Hepatol 2012; 56: 564-570.
21. Sullivan S, Kirk EP, Mittendorfer B, Patterson BW, Klein S: Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatology 2012; 55: 1738-1745.
22. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al: Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121-129.
23. Harrison SA, Fecht W, Brunt EM, Neuschwander- Tetri BA: Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 2009; 49: 80-86.
24. Kirwan JP, Solomon TP, Wojta DM, Staten MA, Holloszy JO: Effects of 7 days of exercise training on insulin sensitivity and responsiveness in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 2009; 297:E151-E156.
25. Van Der Heijden GJ, Wang ZJ, Chu Z, Toffolo G, Manesso E, Sauer PJ, et al: Strength exercise improves muscle mass and hepatic insulin sensitivity in obese youth. Med Sci Sports Exerc 2010; 42: 1973-1980.
26. Thoma C, Day CP, Trenell MI: Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol 2012; 56: 255-266.
27. Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Taylor R, et al: Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 2011; 60: 1278- 1283.
28. Little JP, Gillen JB, Percival ME, Safdar A, Tarnopolsky MA, Punthakee Z, et al: Lowvolume high-intensity interval training reduces hyperglycemia and increases muscle mitochondrial capacity in patients with type 2 diabetes. J Appl Physiol 2011; 111: 1554- 1560.
29. Bacchi E, Negri C, Targher G, Faccioli N, Lanza M, Zoppini G, et al: Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 randomized trial). Hepatology 2013; 58: 1287-1295.
30. NICE: NICE Clinical guidelines. CG43 Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children; in Care NIfHaCEaNCCfP, ed, 2006.
31. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Zvibel I, Goldiner I, et al: Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology 2008; 48: 1791-1798.
32. Hsieh SD, Yoshinaga H, Muto T, Sakurai Y: Regular physical activity and coronary risk factors in Japanese men. Circulation 1998; 97: 661-665.
33. Frith J, Day CP, Robinson L, Elliott C, Jones DE, Newton JL: Potential strategies to improve uptake of exercise interventions in nonalcoholic fatty liver disease. J Hepatol 2010; 52: 112-116.
34. Centis E, Marzocchi R, Suppini A, Dalle Grave R, Villanova N, Hickman IJ, et al: The role of lifestyle change in the prevention and treatment of NAFLD. Curr Pharm Des 2013; 19: 5270-5279.
35. Zivkovic AM, German JB, Sanyal AJ: Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr 2007; 86: 285- 300.
36. Musso G, Gambino R, Pacini G, De Michieli F, Cassader M: Prolonged saturated fat-induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver. Am J Clin Nutr 2009; 89: 558-567.
37. Ryan MC, Itsiopoulos C, Thodis T, Ward G, Trost N, Hofferberth S, et al: The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol 2013; 59: 138-143.
38. Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, et al: Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci 2004; 106: 635-643.
39. Elizondo A, Araya J, Rodrigo R, Poniachik J, Csendes A, Maluenda F, et al: Polyunsaturated fatty acid pattern in liver and erythrocyte phospholipids from obese patients. Obesity 2007; 15: 24-31.
40. Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J: Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012; 56: 944-951.
41. Wong VW, Chan RS, Wong GL, Cheung BH, Chu WC, Yeung DK, et al: Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol 2013; 59: 536-542.
42. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK: Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008; 6: 1396-1402.
43. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE: Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 2004; 39: 1647-1654.
44. Klein S, Mittendorfer B, Eagon JC, Patterson B, Grant L, Feirt N, et al: Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 2006; 130: 1564-1572.
45. Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, et al: Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009; 137: 532-540.
46. Chavez-Tapia NC, Tellez-Avila FI, Barrientos- Gutierrez T, Mendez-Sanchez N, Lizardi- Cervera J, Uribe M: Bariatric surgery for nonalcoholic steatohepatitis in obese patients. Cochrane Syst Rev 2010; 1:CD007340.
47. McPherson S, Anstee QM, Henderson E, Day CP, Burt AD: Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? Eur J Gastroenterol Hepatol 2013; 25: 652-658.
48. NICE: NICE clinical guidelines. CG87 type 2 diabetes: the management of type 2 diabetes. In NICE, ed, 2010.
49. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
50. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
51. Bo S, Benso A, Durazzo M, Ghigo E: Does use of metformin protect against cancer in type 2 diabetes mellitus? J Endocrinol Invest 2012; 35: 231-235.
52. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN: The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-1978.
53. Pollak M: Energy metabolism, cancer risk, and cancer prevention. Recent Results Cancer Res 2009; 181: 51-54.
54. Donadon V, Balbi M, Ghersetti M, Grazioli S, Perciaccante A, Della Valentina G, et al: Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 2009; 15: 2506-2511.
55. Chen HP, Shieh JJ, Chang CC, Chen TT, Lin JT, Wu MS, et al: Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 2013; 62: 606-615.
56. Zhang ZJ, Zheng ZJ, Shi R, Su Q, Jiang Q, Kip KE: Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012; 97: 2347-2353.
57. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-2307.
58. Sanyal AJ, Chalasani N, Kowdley KV, Mc- Cullough A, Diehl AM, Bass NM, et al: Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685.
59. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al: Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008; 135: 1176-1184.
60. Boettcher E, Csako G, Pucino F, Wesley R, Loomba R: Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2012; 35: 66-75.
61. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298: 1180-1188.
62. Lago RM, Singh PP, Nesto RW: Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007; 370: 1129-1136.
63. Piccinni C, Motola D, Marchesini G, Poluzzi E: Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011; 34: 1369- 1371.
64. Lecka-Czernik B: Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep 2010; 8: 178-184.
65. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al: The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592-1609.
66. Nauck MA: A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care 2013; 36: 2126-2132.
67. Armstrong MJ, Houlihan DD, Rowe IA, Clausen WH, Elbrond B, Gough SC, et al: Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. Aliment Pharmacol Ther 2013; 37: 234-242.
68. NICE: NICE clinical guidelines. CG67 Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. In NICE, ed, 2010.
69. Basaranoglu M, Acbay O, Sonsuz A: A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999; 31: 384.
70. Fernandez-Miranda C, Perez-Carreras M, Colina F, Lopez-Alonso G, Vargas C, Solis- Herruzo JA: A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 2008; 40: 200-205.
71. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
72. Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, et al: Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post hoc analysis. Lancet 2010; 376: 1916-1922.
73. El-Serag HB, Johnson ML, Hachem C, Morgana RO: Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 2009; 136: 1601-1608.
74. Chiu HF, Ho SC, Chen CC, Yang CY: Statin use and the risk of liver cancer: a populationbased case-control study. Am J Gastroenterol 2011; 106: 894-898.
75. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W: Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013; 144: 323-332.
76. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923.
77. Dixon JB, Bhathal PS, O'Brien PE: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100.
78. NICE: NICE clinical guidelines. CG127 hypertension: clinical management of primary hypertension in adults. In NICE, ed, 2011.
79. Bataller R, Sancho-Bru P, Gines P, Lora JM, Al-Garawi A, Sole M, et al: Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 2003; 125: 117-125.
80. Paschos P, Tziomalos K: Nonalcoholic fatty liver disease and the renin-angiotensin system: implications for treatment. World J Hepatol 2012; 4: 327-331.
81. Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L: Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension- associated non-alcoholic steatohepatitis. World J Gastroenterol 2009; 15: 942-954.
82. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, et al: Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40: 1222-1225.
83. Al-Mallah M, Khawaja O, Sinno M, Alzohaili O, Samra AB: Do angiotensin-converting enzyme inhibitors or angiotensin receptor blockers prevent diabetes mellitus? A metaanalysis. Cardiol J 2010; 17: 448-456.
84. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al: Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011; 305: 1659-1668.
85. Schurks M, Glynn RJ, Rist PM, Tzourio C, Kurth T: Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ 2010; 341:c5702.
86. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al: Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301: 39-51.
87. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E: Metaanalysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37-46.
88. Romanelli RG, Caligiuri A, Carloni V, De- Franco R, Montalto P, Ceni E, et al: Effect of pentoxifylline on the degradation of procollagen type I produced by human hepatic stellate cells in response to transforming growth factor-? 1 . Br J Pharmacol 1997; 122: 1047- 1054.
89. Preaux AM, Mallat A, Rosenbaum J, Zafrani ES, Mavier P: Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblast-like cells. Hepatology 1997; 26: 315-322.
90. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, et al: Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011; 54: 1610-1619.
91. Ratziu V, Sheikh MY, Sanyal AJ, Lim JK, Conjeevaram H, Chalasani N, et al: A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology 2012; 55: 419-428.
92. Zhang S, Wang J, Liu Q, Harnish DC: Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol 2009; 51: 380-388.
93. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, et al: Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 574-582.e1.
94. Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, et al: Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011; 14: 612-622.
95. Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, et al: Randomized placebo- controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006; 4: 1537-1543.
96. Lin CW, Zhang H, Li M, Xiong X, Chen X, Chen X, et al: Pharmacological promotion of autophagy alleviates steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in mice. J Hepatol 2013; 58: 993-999.
97. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA: Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141: 1249-1253.
98. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G: A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53: 372-384.
99. Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, et al: Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transplant 2001; 7: 363-373.
100. Malik SM, Devera ME, Fontes P, Shaikh O, Sasatomi E, Ahmad J: Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Transplant 2009; 15: 1843-1851.
101. Newsome PN, Allison ME, Andrews PA, Auzinger G, Day CP, Ferguson JW, et al: Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. Gut 2012; 61: 484-500.